{
    "2021-04-29": [
        [
            {
                "time": "",
                "original_text": "【基金必读】华夏嘉实中金等基金经理离任 大摩华鑫新基金延长募集期",
                "features": {
                    "keywords": [
                        "基金经理",
                        "离任",
                        "大摩华鑫",
                        "新基金",
                        "延长募集期"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "“公募一哥”张坤“出手”天坛生物定增，最近半年三次参与定向增发",
                "features": {
                    "keywords": [
                        "公募一哥",
                        "张坤",
                        "天坛生物",
                        "定增",
                        "定向增发"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "“公募一哥”近半年3次出手，这一把浮盈近100%",
                "features": {
                    "keywords": [
                        "公募一哥",
                        "浮盈",
                        "投资收益"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【东北医药崔洁铭】天坛生物（600161）年报季报点评：新产能、新产品有序推进，业绩符合预期",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "新产能",
                        "新产品",
                        "业绩",
                        "预期"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "这类投资火了！“公募一哥”近半年3次出手，这一把浮盈近100%！",
                "features": {
                    "keywords": [
                        "投资",
                        "公募一哥",
                        "浮盈",
                        "投资热度"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}